| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT03322215 |
| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P17 | country | Sweden | Q34 |
| P582 | end time | 2021-10-31 | |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 196 | |
| P4844 | research intervention | capecitabine | Q420207 |
| fulvestrant | Q5508491 | ||
| palbociclib | Q15269707 | ||
| P6153 | research site | Uppsala University | Q185246 |
| Karolinska Institutet | Q219564 | ||
| Sahlgrenska University Hospital | Q3290496 | ||
| NHS Grampian | Q6954137 | ||
| P1813 | short name | PASIPHAE | |
| P859 | sponsor | Theodoros Foukakis | Q41669714 |
| P580 | start time | 2017-10-24 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase 2, International, Multicenter, Open-labeled, Randomized Trial of PAlbociclib and Fulvestrant vs. Standard Oral Capecitabine In Patients With Hormone Receptor (HR)+ / HER2- Advanced Breast Cancer and Documented Endocrine Resistance |
Search more.